Skip to main navigation
Leap therapeutics
Leap therapeutics
  • About
    • About
    • Contact Us
  • Pipeline
    • Pipeline
    • DKN-01 programs
      • Gastric Cancer
      • Colorectal Cancer
      • Endometrial Cancer
      • Prostate Cancer
      • Lung Cancer
    • Anti-CLDN18.2 programs
      • FL-301 (NBL-015)
      • FL-302 (NBL-016)
    • FL-501
  • Science
    • Science
    • DKK1
    • DKN-01
    • Claudin18.2
    • GDF15
  • Patients
    • Patients
    • Expanded Access
  • Careers
  • Investors
    • Investors
    • Stock Information
    • News Releases
    • Presentations & Events
    • Financial Information
    • Corporate Governance
    • Information Request

SEC
Filing

image description

Document Details

Form
10-K
Filing Date
Feb 23, 2018
Document Date
Dec 31, 2017
Form Description
Annual report which provides a comprehensive overview of the company for the past year
Filing Group
Annual Filings
Company
Leap Therapeutics, Inc.
Issuer
LEAP THERAPEUTICS, INC.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
EX-101.INS - EX-101.INS
EX-101.SCH - EX-101.SCH
EX-101.CAL - EX-101.CAL
EX-101.DEF - EX-101.DEF
EX-101.LAB - EX-101.LAB
EX-101.PRE - EX-101.PRE
  • image Print Page Print Page
  • image Email Alerts Email Alerts
  • image Contact Us Contact Us
image description
image description
Leap therapeutics
47 Thorndike Street, Suite B1-1 Cambridge, MA 02141 USA
+1 617 714 0360

Business inquiries
bd@leaptx.com

Investor inquiries
ir@leaptx.com

  • ABOUT
  • CONTACT US
  • CAREERS
  • PIPELINE
  • DKN-01 PROGRAMS
  • ANTI-CLDN18.2 PROGRAMS
  • FL-501
  • PATIENTS
  • EXPANDED ACCESS
  • SCIENCE
  • DKK1
  • DKN-01
  • CLAUDIN18.2
  • GDF15
  • INVESTORS
  • STOCK INFORMATION
  • NEWS RELEASES
  • PRESENTATIONS & EVENTS
  • FINANCIAL INFORMATION
  • CORPORATE GOVERNANCE
  • INFORMATION REQUEST
  • © 2023 Leap Therapeutics, Inc.
  • All Rights Reserved.
  • Terms of Use
  • Privacy Policy
  • Cookie Policy